资源描述：
《Advancing drug therapy of the metabolic syndrome.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。
1、EdiTorialAdvancingdrugtherapyofthemetabolicsyndromeThemetabolicsyndrome—agroupoffactorsthatraisetheriskofcardiovasculardiseaseandtype2diabetes—isincreasinglycommon.Howmightthechallengesofdevelopingimprovedtherapiestonormalizetheseriskfactorsbeapproached?T
2、hemetabolicsyndromeisarapidlygrowingpublicpatientswithseveralriskfactorsistodevelopsinglehealthburden.Obesityisconsideredtobethedrivingdrugsthathavemultipletargetsormodulatetargetsthatforce,becauseitcanelicitallthedefiningcardiometabolicaffectseveralriskf
3、actors3.Forexample,theangiotensinIIriskfactors:atherogenicdyslipidaemia,increasedplasmareceptorblockertelmisartanlowersbloodpressureglucoselevels,increasedbloodpressure,apro-thromboticthroughitsactionontherenin–angiotensinsystemandstateandapro-inflammator
4、ystate.Consequently,first-alsoimprovesdysglycaemiathroughinherentactivityatlinetherapyforthemetabolicsyndromeislifestyletheperoxisomeproliferator-activatedreceptor(PPAR)-γ.change:thatis,weightreductionandincreasedphysicalHowever,ingeneral,thisapproachtoth
5、etreatmentofactivity.Unfortunately,lifestyletherapycanbedifficultmultiplecardiometabolicriskfactorsisatanearlystagetoimplementinpractice,andtheriskfactorsaresubjecttoandposesconsiderablechallenges,asillustratedbytheotherinfluences,suchasgeneticpredisposit
6、ions.So,historyofthedualPPARα–PPARγmodulatormuragli-toeffectivelynormalizetheriskfactorsofthemetabolictazar.Thispotentialdiabetesdrugwasintendedtosyndrome,itisoftennecessarytousedrugs.combinetheestablishedbeneficialeffectsofPPARαHowever,atpresent,theonlya
7、vailablesuchapproachismodulationondyslipidaemiaandofPPARγmodulationtouseseparatedrugstotargeteachriskfactor.Moreover,onhyperglycaemia,butconcernoveritscardiovascularsomeriskfactors,suchashyperglycaemiaintype2dia-safetyledtothediscontinuationofitsdevelopme
8、ntafterbetes,maythemselvesrequiremultipledrugstoachievePhaseIIItrials.adequatecontrol.AlthoughthisapproachhasthebenefitOfcourse,thetwoapproachesabovetotreatmultipleofallowingaphysiciantotitrateandmonitortheefficacyc
